Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
haemophilus b conjugate vaccine (Bharat Biotech)
- Development stage
- Unknown
- Lead developer
- Bharat Biotech
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Biohib is an indigenously developed Haemophilus influenzae type b (Hib) conjugate vaccine developed and manufactured by Bharat Biotech. It consists of purified polyribosyl-ribitol-phosphate (PRP) capsular polysaccharide isolated from an Indian strain (CS-68) of Haemophilus influenzae type b, which is covalently conjugated to a tetanus toxoid carrier protein (PRP-T). This conjugation converts the T-independent polysaccharide antigen into a T-dependent antigen, enhancing immunogenicity and inducing immunological memory in infants and young children. Biohib is indicated for active immunization against invasive diseases caused by Haemophilus influenzae type b, such as meningitis, pneumonia, and septicemia, and is administered via intramuscular injection.
- Brand names
- Biohib
- Other names
- haemophilus b conjugate vaccine (tetanus toxoid conjugate)haemophilus influenzae type b conjugate vaccinepolyribosyl-ribitol-phosphate-tetanus toxoid conjugate vaccinePRP-TPRP-T vaccine
02
Targets
TT (Tetanus toxoid)PRNP (Cellular Prion Protein)
Beyond the preview
Go deeper on haemophilus b conjugate vaccine (Bharat Biotech).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on haemophilus b conjugate vaccine (Bharat Biotech).